NCT06512207View on ClinicalTrials.gov

A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

NARecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 3, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
NSCLC, Stage IIINSCLC, Stage IV
Interventions
DRUG

Leuprorelin acetate + Sintilimab

Leuprolide, an FDA-approved GnRH agonist, reduces sex hormone production and is widely used in clinical practice.

DRUG

Sintilimab

PD-1 inhibitor

Trial Locations (1)

450052

RECRUITING

The Third Oncology Ward, First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

lead

Jinzhou Medical University

OTHER